Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis

Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management

(2014) Kristen K. Miller et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis

(2013) Alyssa Fischer et al.   INVESTIGATIONAL NEW DRUGS

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis

(2013) Viswanath Reddy Belum et al.   INVESTIGATIONAL NEW DRUGS

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

(2012) G. Dranitsaris et al.   ANNALS OF ONCOLOGY

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

(2012) David C. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis

(2011) Yevgeniy Balagula et al.   INVESTIGATIONAL NEW DRUGS

Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword?

(2011) Tina Cascone et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Multikinase inhibitors: a new option for the treatment of thyroid cancer

(2011) Matti L. Gild et al.   Nature Reviews Endocrinology

Risk of Hand-Foot Skin Reaction with the Multitargeted Kinase Inhibitor Sunitinib in Patients with Renal Cell and Non–Renal Cell Carcinoma: A Meta-analysis

(2009) David Chu et al.   Clinical Genitourinary Cancer

Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1α involvement in CYP3A4 repression

(2009) Claire Legendre et al.   EUROPEAN JOURNAL OF CANCER

Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis

(2008) David Chu et al.   ACTA ONCOLOGICA

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

(2008) M. E. Lacouture et al.   ANNALS OF ONCOLOGY